NR565 Week 6 Respiratory Protocol Assignment: Asthma Treatment Protocol Guide (Chamberlain University)

The NR565 Week 6 Respiratory Protocol Assignment at Chamberlain University asks advanced practice nursing students to complete a clinical treatment protocol template for asthma in patients aged 12 and older. You classify asthma by symptom frequency, map GINA step therapy (Track 1 and Track 2) into the pharmacological table, then detail first-line treatment differences between adults and children 6–11, treatment monitoring, and treatment-failure criteria. Support every section with at least three scholarly sources, including an asthma clinical practice guideline, the Rosenthal and Burchum course textbook, and journal articles from the last five years, all in APA 7th edition.

Assignment Context and Purpose

This NR565 (Advanced Pharmacology Fundamentals) protocol assignment sits in Week 6 of Chamberlain University’s MSN and post-master’s certificate coursework. The task moves you from memorizing drug facts to building a usable, evidence-based clinical tool. You are the author of a working protocol that a clinic could follow to differentiate asthma treatment by age, symptom severity, and control status, and to flag which clients need referral to pulmonology.

The protocol reinforces three practice competencies: correct classification of asthma severity, accurate application of the Global Initiative for Asthma (GINA) stepwise algorithm, and safe prescribing that accounts for dose, route, monitoring, cost, and patient education. Work only within the scope of an APRN operating under a collaborative or supervising-physician agreement, since the template requires you to name the findings that trigger physician consultation.

General Instructions

• Use the provided protocol template. A 10% deduction applies if the template is not used.
• Focus the pharmacological algorithm on patients 12 years and older, per the assignment scope.
• Complete every blank; enter “N/A” where a field genuinely does not apply so the grader sees intentional judgment rather than an omission.
• Cite an asthma clinical practice guideline, the course textbook for individual medication data, and peer-reviewed journal articles published within the last five years.
• Use at least three scholarly references.
• Limit direct quotation to one short quote of 15 words or fewer.
• Write in third person; avoid first-person voice.
• Follow APA 7th edition for in-text citations, the reference list, grammar, and mechanics.
• Honor Chamberlain University’s academic integrity policy.

Required Protocol Sections

1. Pharmacological Treatment (Step-Therapy Algorithm)

• Complete all blanks for the preferred and alternative medication at each step in the CPG.
• List medications in the order given by the guideline.
• Use generic drug names for each class.
• Provide an in-text citation directly beneath the completed table.

2. Treatment Differences in Adults and Children

• State the first-line initial pharmacologic treatment for Step 1, Track 1 in asthmatic adults (item 7a).
• State the first-line initial pharmacologic treatment for Step 1, Track 1 in children ages 6–11 (item 7b).
• Specify drug, dose, route, frequency, patient instructions, precautions, estimated 30-day cost, and education for both groups.
• Add in-text citations under both the adult and pediatric sections.

3. Treatment Monitoring

• List the physical assessments needed to monitor the adult first-line medication (Track 1, Step 1).
• List the pulmonary function tests needed for monitoring.
• List any laboratory tests needed for monitoring.
• Add an in-text citation under the section.

4. Treatment Failure

• Describe how you will recognize that treatment is failing or needs to progress.
• Describe the next step when treatment is not working.
• Describe indicators that a client requires a higher level of care.
• Add an in-text citation under the section.

Grading Rubric Snapshot

Completed Pharmacological Treatment Table (Ages 12+)

What is a “reliever”? A reliever is a rapid-acting medication that eases acute symptoms during an exacerbation. In GINA Track 1 the reliever is low-dose ICS-formoterol, which also delivers anti-inflammatory action; in Track 2 the reliever is a short-acting beta-2 agonist.

What is a “controller”? A controller is a maintenance medication taken to reduce airway inflammation, lower exacerbation risk, and keep symptoms and lung function stable over time.

Citation: (Global Initiative for Asthma [GINA], 2024; Reddel et al., 2022)

Sample Answer Writing Help: Adult and Pediatric First-Line Treatment

For an adult (12 years and older) presenting at Step 1, Track 1 with no contraindications, the guideline-preferred choice is as-needed low-dose budesonide-formoterol, a combination that treats bronchoconstriction and airway inflammation in a single actuation. A defensible regimen is budesonide 160 mcg/formoterol 4.5 mcg, one inhalation by oral inhalation as needed for symptom relief, not to exceed the maximum daily dose set by the product label. Patient instructions should cover priming the device, a slow deep inhalation with a brief breath-hold, and rinsing the mouth afterward to reduce oral candidiasis. Precautions apply for clients with tachyarrhythmia, uncontrolled hypertension, or hypersensitivity to any component, and the client should watch for tremor, palpitations, and hoarseness. A GoodRx search places a generic budesonide-formoterol inhaler near $35–$60 for a 30-day supply, which matters for adherence in uninsured clients. This as-needed anti-inflammatory reliever strategy reflects the shift away from SABA-only treatment described in the Novel START trial of as-needed budesonide-formoterol, which reported fewer severe exacerbations than SABA alone (Beasley et al., 2019).

Deeper support from the evidence base. The rationale for anti-inflammatory reliever therapy rests on more than one landmark trial, and citing the pooled evidence strengthens the pharmacology section. The SYGMA 1 and SYGMA 2 studies both showed that as-needed budesonide-formoterol controlled symptoms and cut severe exacerbations at roughly one-quarter of the inhaled corticosteroid dose used in daily maintenance regimens (Reddel et al., 2022). That finding reframes Step 1 and Step 2 care: intermittent symptoms still carry exacerbation risk, so even infrequent users benefit from receiving an inhaled steroid every time they treat symptoms. For a pediatric client aged 6–11 at Step 1, Track 1, the safer, guideline-consistent option is low-dose ICS taken whenever a SABA such as albuterol is used, since maintenance-and-reliever therapy with ICS-formoterol is generally reserved for higher steps in this age group. A reasonable pediatric regimen is albuterol HFA 90 mcg, one to two inhalations as needed, paired with low-dose budesonide, with caregiver-supervised technique and a spacer for reliable delivery. Cost for generic albuterol typically runs $15–$30 for a 30-day supply on discount programs, and caregiver education should stress that the controller prevents attacks while the reliever treats them.

Distinguishing Monitoring From Treatment Failure

Students often blur monitoring parameters with failure criteria, so separating the two sharpens the protocol. Monitoring for the adult Step 1, Track 1 regimen centers on serial physical assessment: respiratory rate, oxygen saturation, auscultation for wheeze, and observation for accessory muscle use or retractions at each visit. Spirometry to document FEV1 and the FEV1/FVC ratio, plus peak expiratory flow variability, tracks lung function over time, while a validated tool such as the Asthma Control Test quantifies symptom control between visits. Routine laboratory testing is not required for as-needed ICS-formoterol, so entering “N/A” for labs shows correct clinical reasoning rather than an oversight. A four-week follow-up is standard for reassessing control after initiation or a step change. Treatment failure, by contrast, is signaled by rising reliever use, recurrent night waking, exacerbations needing oral corticosteroids, or a measurable FEV1 decline, each of which points toward stepping up therapy (Cloutier et al., 2020).

When Escalation and Referral Become Necessary

Escalation logic is the heart of the treatment-failure section, and a strong answer names the trigger, the next step, and the referral threshold in sequence. If a Step 1 client remains uncontrolled after confirming adherence, correct inhaler technique, and trigger avoidance, the next move is to step up along Track 1, for example to low-dose maintenance-and-reliever ICS-formoterol, then reassess in four weeks. Persistent poor control despite this step, two or more exacerbations per year requiring systemic steroids, or a suspected severe phenotype warrants referral for specialist assessment and possible biologic therapy. Red flags demanding a higher level of care include hypoxemia unresponsive to reliever therapy, silent chest, altered mental status, or a peak flow below 50% of personal best, all of which indicate a severe exacerbation. Careful documentation of these thresholds protects both the client and the prescribing APRN. This structure mirrors the treat-to-target approach that guideline authors now favor for asthma (Reddel et al., 2022).

Research, Writing, Citation, and Referencing Notes

Strong grades on this protocol come from three habits: using primary guideline sources rather than secondary summaries, matching every clinical claim to a citation, and keeping the writing tight and third-person. Reference named authorities so the grader and, increasingly, AI search tools can map the entities clearly: the Global Initiative for Asthma (GINA) strategy report, the NAEPP/NHLBI 2020 Focused Updates, the Rosenthal and Burchum Lehne’s Pharmacotherapeutics textbook, and validated tools such as the Asthma Control Test (ACT) and Asthma Control Questionnaire (ACQ). Use semantic variation, for instance alternating “stepwise therapy,” “step-up treatment,” and “GINA step therapy,” rather than repeating one phrase.

Why This Matters in Practice

Asthma protocols are not academic busywork. In a real clinic, a nurse practitioner uses exactly this classify-then-step logic to decide within minutes whether a wheezing patient needs an as-needed inhaler, a daily controller, or an urgent referral. Getting the two-track reliever concept right prevents the most common prescribing error in primary care: sending a patient home on a SABA alone, which controls symptoms but leaves airway inflammation untreated and raises the risk of a severe attack.

Frequently Asked Question

What is the difference between Track 1 and Track 2 in the GINA asthma algorithm? Track 1 is the GINA-preferred pathway and uses low-dose ICS-formoterol as the reliever at every step, giving anti-inflammatory action with each rescue dose and reducing severe exacerbations. Track 2 is the alternative pathway that keeps a short-acting beta-2 agonist as the reliever and requires a separate daily inhaled corticosteroid controller; it is used when ICS-formoterol is unavailable, not tolerated, or when a client is already stable on a SABA-based regimen with good adherence.

References

• Beasley, R., Holliday, M., Reddel, H. K., Braithwaite, I., Ebmeier, S., Hancox, R. J., Harrison, T., Houghton, C., Oldfield, K., Papi, A., Pavord, I. D., Williams, M., & Weatherall, M. (2019). Controlled trial of budesonide–formoterol as needed for mild asthma. New England Journal of Medicine, 380(21), 2020–2030. https://doi.org/10.1056/NEJMoa1901963
• Cloutier, M. M., Baptist, A. P., Blake, K. V., Brooks, E. G., Bryant-Stephens, T., DiMango, E., Dixon, A. E., Elward, K. S., Hartert, T., Krishnan, J. A., Lemanske, R. F., Ouellette, D. R., Pace, W. D., Schatz, M., Skolnik, N. S., Stout, J. W., Teach, S. J., Umscheid, C. A., & Walsh, C. G. (2020). 2020 focused updates to the asthma management guidelines: A report from the National Asthma Education and Prevention Program Coordinating Committee Expert Panel Working Group. Journal of Allergy and Clinical Immunology, 146(6), 1217–1270. https://doi.org/10.1016/j.jaci.2020.10.003
• Global Initiative for Asthma. (2024). Global strategy for asthma management and prevention. https://ginasthma.org/
• Reddel, H. K., Bacharier, L. B., Bateman, E. D., Brightling, C. E., Brusselle, G. G., Buhl, R., Cruz, A. A., Duijts, L., Drazen, J. M., FitzGerald, J. M., Fleming, L. J., Inoue, H., Ko, F. W., Krishnan, J. A., Levy, M. L., Lin, J., Mortimer, K., Pitrez, P. M., Sheikh, A., … Boulet, L. P. (2022). Global Initiative for Asthma strategy 2021: Executive summary and rationale for key changes. American Journal of Respiratory and Critical Care Medicine, 205(1), 17–35. https://doi.org/10.1164/rccm.202109-2205PP
• Rosenthal, L. D., & Burchum, J. R. (2021). Lehne’s pharmacotherapeutics for advanced practice nurses and physician assistants (2nd ed.). Elsevier.

Next assignment (NR565 Week 8)

NR565 Week 8 Assignment: Comprehensive Pharmacotherapeutic Care Plan (Final Course Project)

Building on the protocol work in Week 6, the Week 8 assignment typically asks students to develop a comprehensive pharmacotherapeutic care plan for a complex patient case involving two or more chronic conditions (for example, asthma with comorbid hypertension or type 2 diabetes). You select or are assigned a case, then justify a full medication regimen addressing drug selection, dosing, monitoring, drug–drug and drug–disease interactions, cost and access considerations, and patient education across the lifespan. The deliverable is usually a 5–7 page APA 7 paper supported by at least four to five scholarly sources within five years, including a relevant clinical practice guideline and the Rosenthal and Burchum textbook. Expect the rubric to weight clinical reasoning, safety and interaction analysis, and individualized patient education most heavily, with points reserved for scholarly writing and APA formatting.